Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

Abstract The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy...

Full description

Bibliographic Details
Main Authors: Mimma Rizzo, Andrey Soares, Enrique Grande, Aristotelis Bamias, Ray Manneh Kopp, Edoardo Lenci, Thomas Buttner, Samer Salah, Francesco Grillone, Icaro Thiago de Carvalho, Jose Carlos Tapia, Calogero Gucciardino, Alvaro Pinto, Alessia Mennitto, Halima Abahssain, Pasquale Rescigno, Zin Myint, Hideki Takeshita, Gian Paolo Spinelli, Lazar Popovic, Maria Giuseppa Vitale, Ondrej Fiala, Patrizia Giannatempo, Roubini Zakopoulou, Francesco Carrozza, Francesco Massari, Fernando Sabino Marques Monteiro, Maria Paola Pace, Massimo Giannini, Giandomenico Roviello, Camillo Porta, Nicola Battelli, Ravindran Kanesvaran, Matteo Santoni
Format: Article
Language:English
Published: Nature Portfolio 2024-08-01
Series:Scientific Reports
Subjects:
ARON-2 study
Pembrolizumab
Radiation therapy
Stereotactic radiation therapy
Urothelial carcinoma
Real-world data
Online Access:https://doi.org/10.1038/s41598-024-70182-3

Internet

https://doi.org/10.1038/s41598-024-70182-3

Similar Items